<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03853109</url>
  </required_header>
  <id_info>
    <org_study_id>20180143</org_study_id>
    <nct_id>NCT03853109</nct_id>
  </id_info>
  <brief_title>AMG 404 in Patients With Advanced Solid Tumors.</brief_title>
  <official_title>A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 404, a Programmed Death-1 (PD-1) Antibody, in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and tolerability of AMG 404, a monoclonal antibody that binds to PD-1&#xD;
      and inhibits its engagement with ligands, in patients with advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 5, 2019</start_date>
  <completion_date type="Anticipated">February 17, 2026</completion_date>
  <primary_completion_date type="Anticipated">March 12, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subject incidence of Dose limiting toxicities (DLTs)</measure>
    <time_frame>28 Days</time_frame>
    <description>Dose limiting toxicities (DLTs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subject incidence of treatment emergent adverse events</measure>
    <time_frame>28 Days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Subject incidence of treatment related adverse events</measure>
    <time_frame>28 Days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Subject incidence of changes in vital signs</measure>
    <time_frame>28 Days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Subject incidence of clinical laboratory tests</measure>
    <time_frame>28 Days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed concentration (Cmax) of AMG 404</measure>
    <time_frame>24 months</time_frame>
    <description>Pharmacokinetic (PK) analysis of AMG 404</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed concentration (Tmax) of AMG 404</measure>
    <time_frame>24 months</time_frame>
    <description>Pharmacokinetic (PK) analysis of AMG 404</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration-time curve (AUC) of AMG 404</measure>
    <time_frame>24 months</time_frame>
    <description>Pharmacokinetic (PK) analysis of AMG 404</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject incidence of anti-AMG 404 antibodies</measure>
    <time_frame>24 months</time_frame>
    <description>Assess immunogenicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective tumor response</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of overall response</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of stable disease</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">235</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 7</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 8</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 9</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 404</intervention_name>
    <description>AMG 404 will be examined for safety, tolerability, PK, and PD of AMG 404 in subjects with advanced solid tumors.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_label>Cohort 7</arm_group_label>
    <arm_group_label>Cohort 8</arm_group_label>
    <arm_group_label>Cohort 9</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject has provided informed consent prior to initiation of any study specific&#xD;
             activities/procedures.&#xD;
&#xD;
          -  Age greater than or equal to 18 years old at the time of signing informed consent.&#xD;
&#xD;
          -  Life expectancy of greater than 3 months, in the opinion of the investigator&#xD;
&#xD;
          -  Subject must have histologically or cytologically confirmed metastatic or locally&#xD;
             advanced solid tumors not amenable to curative treatment with surgery or radiation.&#xD;
&#xD;
          -  At least 1 measurable as defined by modified RECIST 1.1 which has not undergone biopsy&#xD;
             within 3 months of the screening scan. This lesion cannot be biopsied at any time&#xD;
             during the study. Note: if there is only one lesion available for biopsy and&#xD;
             radiographic assessment, it may be permitted to be biopsied after discussion with&#xD;
             sponsor.&#xD;
&#xD;
          -  Subjects with treated brain metastases are eligible provided they meet the following&#xD;
             criteria: Definitive therapy was completed at least 2 weeks prior to enrollment. No&#xD;
             evidence of radiographic CNS progression or CNS disease following definitive therapy&#xD;
             and by the time of study screening. Patients manifesting progression in lesions&#xD;
             previously treated with stereotactic radiosurgery may still be eligible if&#xD;
             pseudoprogression can be demonstrated by appropriate means and after discussion with&#xD;
             the medical monitor.&#xD;
&#xD;
          -  Any CNS disease is asymptomatic, any neurologic symptoms due to CNS disease have&#xD;
             returned to baseline or are deemed irreversible, the patient is off steroids for at&#xD;
             least 7 days (physiologic doses of steroids are permitted), and the patient is off or&#xD;
             on stable doses of anti-epileptic drugs for malignant CNS disease.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of less than or equal to&#xD;
             2.&#xD;
&#xD;
          -  Hematologic function, as follows without growth factor support within 2 weeks prior to&#xD;
             study day 1: Absolute neutrophil count (ANC) greater than or equal to 1.0 x 10E9/L;&#xD;
             Platelet count greater than or equal to 75 x 10E9/L; Hemoglobin greater than or equal&#xD;
             to 9 g/dL (90 g/L).&#xD;
&#xD;
          -  Adequate renal laboratory assessments, as follows: Estimated glomerular filtration&#xD;
             rate based on MDRD (Modification of Diet in Renal Disease) calculation . 60&#xD;
             ml/min/1.73 m2 for Cohorts 1, 2, 4, and 5.&#xD;
&#xD;
        Estimated glomerular filtration rate based on MDRD (Modification of Diet in Renal Disease)&#xD;
        calculation . 45 ml/min/1.73 m2 for Cohorts 3, 6, 7, 8 and 9.&#xD;
&#xD;
          -  Hepatic function, as follows: Total bilirubin less than or equal to 1.5 x ULN or less&#xD;
             than or equal to 3 x ULN for subjects with liver metastasis; AST less than or equal to&#xD;
             3 x ULN or less than or equal to' 5 x ULN for subjects with liver metastasis; ALT less&#xD;
             than or equal to 3 x ULN or less than or equal to 5 x ULN for subjects with liver&#xD;
             metastasis; Alkaline phosphatase less than or equal to 2.5 x ULN or less than or equal&#xD;
             to 5 x ULN for subjects with liver metastasis (Note: elevated alkaline phosphatase is&#xD;
             acceptable if it is due to non-hepatic associated pathology [eg, bone disease]).&#xD;
&#xD;
          -  Cohort 5 only: Subject is a resident in China of Chinese ancestry.&#xD;
&#xD;
          -  Subjects enrolled to Cohorts 7-9, must submit tumor tissue sample. Fresh tumor&#xD;
             biopsies may be performed if subject has a readily accessible tumor lesion and who&#xD;
             consent to the biopsies. If fresh biopsies cannot be obtained, archival tumor samples&#xD;
             are acceptable. Prior to enrollment it is required to determine that there is enough&#xD;
             tumor tissue available to be sent to the central laboratory: Cohorts 7 and 9: Archival&#xD;
             tissue collected up to 12 months prior to screening date is permitted. Biopsies&#xD;
             collected between 12-18 months prior to screening are allowed upon discussion with the&#xD;
             medical monitor. Subjects with EBV associated nasopharyngeal carcinoma may submit&#xD;
             biopsy with EBV test results from within 36 months prior to screening; Cohort 8:&#xD;
             Archival tissue with MSI-high/dMMR test results collected up to 36 months prior to&#xD;
             screening date is permitted.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Disease Related. Primary brain tumor, untreated or symptomatic brain metastases and&#xD;
             leptomeningeal disease (exception: benign asymptomatic tumors are permitted).&#xD;
&#xD;
          -  Other Medical Conditions. History of other malignancy within the past 2 years, with&#xD;
             the following exception[s]: Malignancy treated with curative intent and with no known&#xD;
             active disease present for greater than or equal to 2 years before enrollment and felt&#xD;
             to be at low risk for recurrence by the treating physician. Adequately treated&#xD;
             non-melanoma skin cancer or lentigo maligna without evidence of disease. Adequately&#xD;
             treated cervical carcinoma in situ without evidence of disease. Adequately treated&#xD;
             breast ductal carcinoma in situ without evidence of disease. Prostatic intraepithelial&#xD;
             neoplasia without evidence of prostate cancer. Adequately treated urothelial papillary&#xD;
             noninvasive carcinoma or carcinoma in situ. Other malignancies which do not require&#xD;
             systemic therapy, may be considered upon discussion with the medical monitor.&#xD;
&#xD;
          -  History of solid organ transplantation.&#xD;
&#xD;
          -  Major surgery within 28 days of study day 1.&#xD;
&#xD;
          -  Prior/Concomitant Therapy: Prior treatment with anti-programmed death 1 (PD-1),&#xD;
             anti-PD-L1, CTLA-4 or other checkpoint inhibitor drugs.&#xD;
&#xD;
          -  Anti-tumor therapy (radiotherapy, chemotherapy, antibody therapy, molecular targeted&#xD;
             therapy, or investigational agent) within 21 days prior to study day 1. Note:&#xD;
             Palliative radiotherapy is permitted.&#xD;
&#xD;
          -  Live vaccine therapy within 4 weeks prior to study drug administration.&#xD;
&#xD;
          -  Current treatment or within 14 days of day 1 with immunosuppressive corticosteroid&#xD;
             defined as greater than 10 mg prednisone daily or equivalent. Corticosteroids with no&#xD;
             or minimal systemic effect (such as topical or inhalation) are permitted. Note:&#xD;
             Corticosteroids &gt; 10 mg prednisone used for management of contrast allergy for study&#xD;
             scans is allowed.&#xD;
&#xD;
          -  Prior/Concurrent Clinical Study Experience: Currently receiving treatment in another&#xD;
             investigational device or drug study, or less than 21 days prior to study day 1 since&#xD;
             ending treatment on another investigational device or drug study(ies).&#xD;
&#xD;
          -  Diagnostic Assessments: Evidence of interstitial lung disease or active,&#xD;
             non-infectious pneumonitis.&#xD;
&#xD;
          -  History of any immune-related colitis. Infectious colitis is allowed if evidence of&#xD;
             adequate treatment and clinical recovery exists and at least 3 months interval&#xD;
             observed since diagnosis of colitis.&#xD;
&#xD;
          -  History of allergic reactions or acute hypersensitivity reaction to antibody&#xD;
             therapies.&#xD;
&#xD;
          -  Positive/Non-negative test for Human Immunodeficiency Virus (HIV).&#xD;
&#xD;
          -  Has known active Hepatitis B (eg, hepatitis B antigen [HBsAg] reactive) or Hepatitis C&#xD;
             (eg, HCV RNA [qualitative] is detected).&#xD;
&#xD;
          -  Subject currently has an active infection requiring systemic therapy.&#xD;
&#xD;
          -  Active or history of any autoimmune disease or immunodeficiencies. Subjects with Type&#xD;
             I diabetes, vitiligo, psoriasis, hypo- or hyper- thyroid disease not requiring&#xD;
             immunosuppressive treatment are permitted.&#xD;
&#xD;
          -  Myocardial infarction within 6 months of study day 1, symptomatic congestive heart&#xD;
             failure (New York Heart Association greater than class II), unstable angina, or&#xD;
             cardiac arrhythmia requiring antiarrhythmic medication.&#xD;
&#xD;
          -  Unresolved toxicities from prior anti-tumor therapy, defined as not having resolved to&#xD;
             Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 grade 1, or are&#xD;
             stable and well controlled with minimal, local, or non-invasive intervention AND there&#xD;
             is agreement to allow by both the investigator and the Amgen Medical Monitor.&#xD;
&#xD;
          -  Other Exclusions: Males and females of reproductive potential who are unwilling to&#xD;
             practice highly effective methods of birth control while on study through 6 months&#xD;
             (females) and 8 months (males) after receiving the last dose of study drug.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amgen Call Center</last_name>
    <phone>866-572-6436</phone>
    <email>medinfo@amgen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sarcoma Oncology Research Center LLC</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute at HealthONE</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Louisville James Graham Brown Cancer Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wake Forest Baptist Health</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chris OBrien Lifehouse</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Queen Elizabeth Hospital</name>
      <address>
        <city>Woodville South</city>
        <state>South Australia</state>
        <zip>5011</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nucleo de Oncologia da Bahia</name>
      <address>
        <city>Salvador</city>
        <state>Bahia</state>
        <zip>40170-110</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Sao Lucas da Pontificia Universidade Catolica do Rio Grande do Sul</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90610-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sociedade Beneficente de Senhoras Hospital Sirio Libanes</name>
      <address>
        <city>Sao Paulo</city>
        <state>São Paulo</state>
        <zip>01308-050</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de Base de Sao Jose do Rio Preto</name>
      <address>
        <city>São José do Rio Preto</city>
        <state>São Paulo</state>
        <zip>15090-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto Coi</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>22793-080</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East</name>
      <address>
        <city>Kashiwa-shi</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Shikoku Cancer Center</name>
      <address>
        <city>Matsuyama-shi</city>
        <state>Ehime</state>
        <zip>791-0280</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wakayama Medical University Hospital</name>
      <address>
        <city>Wakayama-shi</city>
        <state>Wakayama</state>
        <zip>641-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Severance Hospital Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea Seoul St Marys Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne</name>
      <address>
        <city>Gdansk</city>
        <zip>80-214</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Narodowy Instytut Onkologii im Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy</name>
      <address>
        <city>Warszawa</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National University Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>119074</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Centre Singapore</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d Hebron</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Linkou Chang Gung Memorial Hospital of Chang Gung Medical Foundation</name>
      <address>
        <city>Taoyuan</city>
        <zip>33305</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Doktor Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastirma Hastanesi</name>
      <address>
        <city>Ankara</city>
        <zip>06200</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Koc Universitesi Hastanesi</name>
      <address>
        <city>Istanbul</city>
        <zip>34010</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ege Universitesi Ilac Gelistirme ve Farmakokinetik Arastirma Uygulama Merkezi (ARGEFAR)</name>
      <address>
        <city>Izmir</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute UK</name>
      <address>
        <city>London</city>
        <zip>W1G 6AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 22, 2019</study_first_submitted>
  <study_first_submitted_qc>February 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2019</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.</ipd_time_frame>
    <ipd_access_criteria>Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.</ipd_access_criteria>
    <ipd_url>https://www.amgen.com/datasharing</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

